UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

Benzinga Newsdesk www.benzinga.com Neutral 81.8%

Neg 0% Neu 81.8% Pos 0%

UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.